Baker Justin J, Stitzenberg Karyn B, Collichio Frances A, Meyers Michael O, Ollila David W
Division of Surgical Oncology, Department of Surgery, Maine Medical Center, Portland, Maine, USA.
Am Surg. 2014 Aug;80(8):805-10.
Studies of ipilimumab have shown improved overall survival in patients with metastatic cutaneous melanoma. As a result, use of ipilimumab in patients with Stage IV melanoma is rapidly increasing. Patients with Stage IV melanoma often require urgent operations for complications from metastases, but little is known about the safety of surgical intervention for patients receiving ipilimumab. We performed a systematic review of the literature using PubMed. Our search terms were melanoma and ipilimumab. We excluded foreign language articles, review articles, and those not addressing cutaneous melanoma. We identified 194 publications matching the search criteria. Only six of those met the inclusion criteria. In these six publications, seven patients who had undergone surgical intervention during treatment with ipilimumab were described. There were no documented surgical complications. We reviewed our institutional experience and identified an additional three patients. No postoperative complications could be attributed directly to ipilimumab. There are limited data on the safety of surgical intervention during treatment with ipilimumab. Preliminary reports suggest there is no reason to withhold or delay surgery for patients receiving ipilimumab therapy.
对伊匹单抗的研究表明，转移性皮肤黑色素瘤患者的总生存期有所改善。因此，伊匹单抗在IV期黑色素瘤患者中的使用正在迅速增加。IV期黑色素瘤患者常因转移并发症而需要紧急手术，但对于接受伊匹单抗治疗的患者进行手术干预的安全性知之甚少。我们使用PubMed对文献进行了系统回顾。我们的检索词是黑色素瘤和伊匹单抗。我们排除了外语文章、综述文章以及未涉及皮肤黑色素瘤的文章。我们确定了194篇符合检索标准的出版物。其中只有6篇符合纳入标准。在这6篇出版物中，描述了7例在接受伊匹单抗治疗期间接受手术干预的患者。没有记录到手术并发症。我们回顾了我们机构的经验，并确定了另外3例患者。没有术后并发症可直接归因于伊匹单抗。关于伊匹单抗治疗期间手术干预安全性的数据有限。初步报告表明，没有理由对接受伊匹单抗治疗的患者延迟或拒绝手术。
